Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT06242327
Recruiting Observational

An Outcome Analysis of Primary Membranous Nephropathy

NCT06242327 · tracked via the Priya Life Science Italy tracker
Sponsor
Mario Negri Institute for Pharmacological Research
Phase
Observational
Started
2024-11-29
Last updated
2026-03-23

Condition(s) studied

Membranous Nephropathy

Study summary

This is an observational study intended to track the course of the primary membranous nephropathy disease in real-world clinical practice.

The study will primarily assess the long-term outcomes of patients with primary membranous nephropathy in the context of advances in treatment options.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adults (≥18 years old) on the day of signing informed consent. * Diagnosis of primary membranous nephropathy * Nephrotic syndrome (proteinuria \>3.5 g/24 hours) * Written informed consent to the use of recorded data for research purposes. Exclusion Criteria: * Legal incapacity or limited legal capacity. * Any contraindication to treatment with rituximab or other monoclonal antibody

Primary outcome measure(s)

  • Evaluation of disease remission — Through study completion, an average of 6 months
    Combined endpoint of complete (proteinuria \< 0.3 g/24-hours) or partial (proteinuria \<3 g/24-hours with \>50% change vs proteinuria at baseline that is the time of the first rituximab or other monoclonal antibody administration) remission

Trial sites (2)

FacilityCityRegionStatus
ASST HPG23 - Unità di Nefrologia Bergamo BG Active Not Recruiting
Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò" Ranica BG Recruiting

More Mario Negri Institute for Pharmacological Research trials in Italy

Evaluation of the Quality of Care in the Emergency Department by Studying the Appropriateness of Admissions of Patients Accessing the Emergency Department (ASST Papa Giovanni XXIII) Active, not recruiting
Simulated and Synthetic Health Data: Improving Clinical Research on Rare Diseases. A Real-World Data Simulation of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Trials. A Retrospective, Observational Study Active, not recruiting
Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases Recruiting
Severe Acquired Brain Injuries: Prognostic Factors and Quality of Care Recruiting
Health-care Quality in Semi-intensive Care Units Recruiting

Other trials for the same condition

Omics of Rituximab-resistance Starting soon
Autoreactive B Cells in Membranous Nephropathy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06242327 on ClinicalTrials.gov ↗ ← All trials in Italy